Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IRWD Ironwood Pharmaceuticals
11.400-0.140-1.21%
Close
02/03 16:00 ET
11.4000.0000.00%
Post Mkt Price 02/03 16:04 ET
High
11.695
Open
11.490
Turnover
26.08M
Low
11.310
Pre Close
11.540
Volume
2.28M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023.
International Biotechnology Trust PLC Has $621,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
International Biotechnology Trust PLC boosted its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 8,570.5% in the 3rd quarter, according to its most recent Form 13F f
Equities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s Q4 2022 Earnings (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) – Analysts at Capital One Financial lowered their Q4 2022 earnings estimates for Ironwood Pharmaceuticals in a research report issued to cl
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Comerica Bank
Comerica Bank trimmed its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 22.1% in the 3rd quarter, according to the company in its most recent 13F filing with the
Allspring Global Investments Holdings LLC Has $3.04 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Allspring Global Investments Holdings LLC grew its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 4.1% in the 3rd quarter, according to its most recent filing with the Secu
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Are up 3.7% This Past Week, but Still in the Red Over the Last Five Years
Assenagon Asset Management S.A. Buys 11,527 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Assenagon Asset Management S.A. grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 8.5% in the third quarter, according to the company in its most recent filing
Monarch Partners Asset Management LLC Buys 31,125 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Monarch Partners Asset Management LLC grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 11.4% in the 3rd quarter, according to its most recent filing with the Securities
We Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Insider Sell: Ironwood Pharmaceuticals
04:11 PM EST, 01/09/2023 (MT Newswires) -- Thomas A McCourt, Director, Chief Executive Officer, on January 05, 2023, sold 110,962 shares in Ironwood Pharmaceuticals (IRWD) for $1,339,311. Following th
Company Overview
More
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
CEO： Mr. Thomas A. McCourt
Market： NASDAQ
Listing Date： 02/03/2010
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet